Clinical Trials Logo

Acne Vulgaris clinical trials

View clinical trials related to Acne Vulgaris.

Filter by:

NCT ID: NCT03615768 Completed - Acne Vulgaris Clinical Trials

A Study to Evaluate the Efficacy and Safety of Adapalene-Clindamycin Combination Gel in the Treatment of Acne Vulgaris

Start date: August 14, 2018
Phase: Phase 3
Study type: Interventional

This is a study to see if Adapalene-Clindamycin Combination Gel is effective and safe in the treatment of acne vulgaris, compared to adapalene gel alone and clindamycin gel alone. Adapalene and clindamycin have been reported to have a better effect in acne treatment when used together. This new formulation is also easier to use as it combines two products into a single gel and only needs to be used once a day.

NCT ID: NCT03602534 Not yet recruiting - Acne Vulgaris Clinical Trials

Thyroid Dysfunction in Female Patients With Acne Vulgaris: [ Relation to Other Variables ]

Start date: December 2018
Phase:
Study type: Observational

Acne is a chronic inflammatory disease of the pilo-sebaceous unit with a multi-factorial etiology. It is one of the most frequent cutaneous diseases, affecting more than eighty percent of the population at some point in their lives . Endocrine factors especially androgens and steroids are one of multiple factors provoked to be involved in pathogenesis of acne . Thyroid hormones have steroid like action that have many regulatory functions in many body organ functions including skin and pilosebaceous unit. Furthermore, subtle thyroid dysfunction was shown to have a role in many disease conditions. Thyroid hormone action on sebaceous glands is unclear. In hypothyroid states, sebocytes exhibit reduced rates of secretion that increases with thyroxine administration .

NCT ID: NCT03599193 Completed - Acne Vulgaris Clinical Trials

A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris

Start date: October 4, 2017
Phase: Phase 2
Study type: Interventional

This was a multicenter, randomized, multiple-dose, laboratory-blinded, open-label, 2-arm, parallel-arm study in subjects with moderate acne vulgaris.

NCT ID: NCT03585140 Completed - Acne Vulgaris Clinical Trials

Low Glycemic Index and Load Diet for the Treatment of Acne

Start date: January 1, 2016
Phase: N/A
Study type: Interventional

Clinical trial to determine the effect of adding a diet with low glycemic index and load to adults for the treatment of moderate acne. Adult patients with acne where recruited in two groups, A and B. Group A received a normal diet according to their metabolic status and group B received a diet with low glycemic index and load. Outcomes were measured at week 12.

NCT ID: NCT03573518 Completed - Acne Vulgaris Clinical Trials

Evaluation of BTX 1503 in Patients With Moderate to Severe Acne Vulgaris

Start date: June 26, 2018
Phase: Phase 2
Study type: Interventional

The objective of this study is to assess safety and efficacy of various doses of BTX 1503 liquid formulation in subjects with moderate to severe acne vulgaris of the face.

NCT ID: NCT03573115 Completed - Acne Vulgaris Clinical Trials

Multimodal Optical Imaging for Pretreatment Evaluation for Cutaneous Microparticle Delivery

Start date: January 4, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate how pretreatment with a topical medication for acne affects application and delivery of gold microparticles to the skin in acne patients. In addition, the investigators want to investigate the biodistribution of gold microparticles in pretreated skin and compare this with the biodistribution of untreated skin using the non-invasive imaging techniques optical coherence tomography and reflectance confocal microscopy

NCT ID: NCT03563365 Terminated - Acne Vulgaris Clinical Trials

The Functional and Emotional Benefits of Replenix Power of Three With Resveratrol

Start date: June 4, 2018
Phase: Phase 4
Study type: Interventional

A Randomized, Investigator Blinded, Single Site, Three Arm Clinical Study to Assess the Functional and Emotional Benefits of Replenix Power of Three Cream with Resveratrol , Replenix Power of Three Cream with Resveratrol with Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5%, and Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5%, utilized to treat subjects with Facial Acne Vulgaris

NCT ID: NCT03536637 Completed - Acne Vulgaris Clinical Trials

DMT310-001 Topical in the Treatment of Acne Vulgaris

Start date: May 22, 2018
Phase: Phase 2
Study type: Interventional

The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne vulgaris.

NCT ID: NCT03524040 Completed - Acne Vulgaris Clinical Trials

Imaging of Pilosebaceous Units and Acne Lesions by RCM and OCT Confocal Microscopy and Optical Coherence Tomography

Start date: December 2016
Phase: N/A
Study type: Interventional

The purpose of the study was to investigate if reflectance confocal microscopy (RCM) and optical coherence tomography (OCT) could be used in combination to investigate the morphology of pilosebaceous units and acne lesions in healthy subjects and in acne patients.Furthermore, to investigate contrast effects, biodistribution and selective photothermolysis provided by gold microparticles and diode laser pulses, using RCM, OCT and histology.

NCT ID: NCT03522922 Completed - Acne Vulgaris Clinical Trials

Efficacy of Microneedling With Topical Vitamin C in Treatment of Acne Scarring

Start date: June 1, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

This study aimed to evaluate the efficacy of dermaroller and topical vitamin C- either separate or combined- in treatment of post acne scars. prospective randomized clinical trial that was The study was a randomized controlled trial, conducted in Sohag Dermatology outpatient clinic between June 2016 and of February 2018. 30 patients with acne scars were included. All patients were informed about the entire procedure, medication, possible side effects and outcomes. A written informed consent was signed from each participant.